Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Myelodysplastic Syndromes and EHA 2025

The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Synthetic cohorts and digital twin technology to address elderly underrepresentation in trials 1:54
Synthetic cohorts and digital twin technology to address elderly underrepresentation in trials
Alfonso Piciocchi • 24 Jun 2025
Interim efficacy analysis of azacitidine and venetoclax in previously untreated and HMA-failure MDS 3:43
Interim efficacy analysis of azacitidine and venetoclax in previously untreated and HMA-failure MDS
Ian Bouligny • 19 Jun 2025
A Phase II trial of three-day decitabine, three-day azacitidine, or five-day azacitidine in LR-MDS 4:17
A Phase II trial of three-day decitabine, three-day azacitidine, or five-day azacitidine in LR-MDS
Ian Bouligny • 19 Jun 2025
Challenges and advances in the treatment of HR-MDS: alloSCT and novel agents 1:06
Challenges and advances in the treatment of HR-MDS: alloSCT and novel agents
Idoroenyi Amanam • 15 Jun 2025
Luspatercept versus epoetin alfa in the COMMANDS trial: overall survival after two and a half years 1:14
Luspatercept versus epoetin alfa in the COMMANDS trial: overall survival after two and a half years
Valeria Santini • 15 Jun 2025
The use of immunosuppressive therapy in MDS: available agents and areas for further research 3:59
The use of immunosuppressive therapy in MDS: available agents and areas for further research
Valeria Santini • 15 Jun 2025
ALLG BM12 CAST: post-transplant cyclophosphamide for GvHD prophylaxis in stem cell transplantation 4:20
ALLG BM12 CAST: post-transplant cyclophosphamide for GvHD prophylaxis in stem cell transplantation
David Curtis • 15 Jun 2025
The effectiveness of sequential alloSCT in patients with venetoclax-exposed R/R AML or MDS-IB2 3:29
The effectiveness of sequential alloSCT in patients with venetoclax-exposed R/R AML or MDS-IB2
Andrius Žučenka • 15 Jun 2025
Real-world outcomes for US patients with LR-MDS treated with first-line luspatercept 1:51
Real-world outcomes for US patients with LR-MDS treated with first-line luspatercept
Idoroenyi Amanam • 15 Jun 2025
An overview of the current interventions for patients with LR-MDS and anemia 5:49
An overview of the current interventions for patients with LR-MDS and anemia
Valeria Santini • 15 Jun 2025
IMerge trial update: outcomes with imetelstat in patients with ring sideroblast negative LR-MDS 2:37
IMerge trial update: outcomes with imetelstat in patients with ring sideroblast negative LR-MDS
Valeria Santini • 15 Jun 2025
Lisaftoclax plus azacitidine for treatment-naïve or venetoclax-exposed myeloid malignancies 0:57
Lisaftoclax plus azacitidine for treatment-naïve or venetoclax-exposed myeloid malignancies
Shaun Fleming • 14 Jun 2025
Early findings of LAVA-1266, a CD123-targeting Vγ9Vδ2-T cell engager, in R/R AML and HR-MDS 1:16
Early findings of LAVA-1266, a CD123-targeting Vγ9Vδ2-T cell engager, in R/R AML and HR-MDS
Shaun Fleming • 14 Jun 2025
Considering patient-reported fatigue in MDS: a novel prognostic index 0:59
Considering patient-reported fatigue in MDS: a novel prognostic index
Fabio Efficace • 14 Jun 2025
The burden of disease in patients with VEXAS syndrome and the need for further research 0:54
The burden of disease in patients with VEXAS syndrome and the need for further research
Fabio Efficace • 14 Jun 2025
Results of the BEXMAB study: efficacy of bexmarilimab plus azacitidine in MDS 2:40
Results of the BEXMAB study: efficacy of bexmarilimab plus azacitidine in MDS
Mika Kontro • 14 Jun 2025

The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).

Silver Supporter

Geron

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

If you are interested in becoming a supporter of The Myelodysplastic Syndromes Channel, please contact us.

The content of VJHemOnc is intended for healthcare professionals